Ren Jing

Dr. Ren Jing

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Hereditas
Verified
Journal Article
Open access
PDF file
HXHai Xie
Hai Xie
RJRen Jing
Ren Jing
XLXiaoting Liao
Xiaoting Liao
HCHaishao Chen
Haishao Chen
XXXianlong Xie
Xianlong Xie
LPLinghui Pan
Linghui Pan
Background: Arecoline is a well-known risk factor for oral submucosal fibrosis and cancer. However, the mechanistic correlation between arecoline and hepatocellular cancer remains elusive. Here, we investigated the effect of arecoline on the proliferation and migration of human HepG2 hepatoma cells and its potential oncogenic mechanisms.Methods: Bioinformatic technologies were used to identify the deferentially expressed miRNAs (DE-miRNAs) and hub target genes of arecoline-induced cancers. These DE-miRNAs, hub genes and pathway were proved in arecoline-treated HepG2 cells.Results: A total of 86 DE-miRNAs and 460 target genes were identified. These target genes are associated with DNA-templated regulation of transcription and other biological processes. Significant molecular functions were protein binding, calcium ion binding, and enrichment in the nucleus and cytoplasm. These genes are involved in the PI3K-AKT pathway. CDK1, CCND1, RAF1, CDKN1B and BTRC were defined as the top 5 hub target genes, and patients with high expression of CDK1 showed poor prognosis. Compared with control group, 2.5 µM arecoline treatment increased the proliferation and migration ability of the HepG2 cells. Treatment with 2.5 µM arecoline increased the levels of miR-21-3p, miR-21-5p and miR-1267, upregulated the expression of PI3K-AKT pathway factors, CDK1, CCND1 but decreased RAF1 expression.Conclusion: A low concentration arecoline can induce the proliferation and migration of HepG2 cells, with the potential mechanism of action linked to high levels of exosomal miR-21 and miR-1267, activation of the PI3K-AKT pathway, upregulation of CDK1 and CCND1, and downregulation of RAF1.

23 June 2025 in Journal of Affective Disorders
Verified
Journal Article
Closed access
JLJiangli Lan
Jiangli Lan
YZYanqiong Zhou
Yanqiong Zhou
LDLingyan Deng
Lingyan Deng
HLHuan Liu
Huan Liu
WHWei Hong
Wei Hong
JZJianqiu Zheng
Jianqiu Zheng

24 April 2026 in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Verified
Journal Article
Closed access
YHYaoli Hou
Yaoli Hou
ZZZhiying Zeng
Zhiying Zeng
SHSheng He
Sheng He
LHLili He
Lili He
KLKun Liu
Kun Liu
RJRen Jing
Ren Jing
Immunosenescence—the age-related decline of immune function—drives a state of chronic, sterile inflammation termed inflammaging. Far from passive deterioration, this process is actively orchestrated by distinct but interconnected hallmarks: erosion of lymphoid organs, myeloid-biased hematopoiesis, accumulation of immune-evasive senescent cells, and metabolic-epigenetic reprogramming that locks cells into dysfunctional states. These core nodes form a self-perpetuating cycle that propagates pathology across multiple organ systems, fueling neurodegeneration, cancer, musculoskeletal decline, and gut dysbiosis. Critically, the field has transitioned from descriptive phenomenology to mechanism-based intervention. This review synthesizes emerging therapeutic strategies targeting specific nodes of the immunosenescence network. We examine senotherapeutics that sensitize senescent cells for immune clearance, HSC and thymic rejuvenation to restore lymphocyte production, and metabolic-epigenetic interventions to correct intracellular deficits. By integrating these insights, we propose a precision medicine framework that moves beyond broad immunosuppression toward rational combinatorial regimens. This roadmap aims to decouple protective immunity from pathological drivers, extending healthspan and redefining the paradigm of geriatric care.

26 May 2026 in Medcomm
Verified
Journal Article
Open access
YHYaoli Hou
Yaoli Hou
SHSheng He
Sheng He
LHLili He
Lili He
KLKun Liu
Kun Liu
WTWen Tang
Wen Tang
RJRen Jing
Ren Jing
Acute lung injury (ALI) and its severe manifestation, acute respiratory distress syndrome (ARDS), remain critical conditions with persistently high mortality. The failure to develop effective pharmacotherapies stems largely from reductionist approaches focused on isolated linear pathways. This review synthesizes recent breakthroughs redefining ALI as dysregulation of integrated pathological networks spanning immunity, metabolism, and cell death. We systematically analyze three interconnected core circuits: cGAS–STING as a central danger signal integrator, immunometabolic reprogramming as fuel for sustained inflammation, and the programmed cell death network—particularly PANoptosis—as executor of tissue damage. We further elucidate how ALI manifests as a multiorgan communication disorder, with the brain and gut actively shaping pulmonary inflammation. The convergence of single‐cell technologies, multiomics profiling, and computational modeling has deconstructed ARDS heterogeneity into clinically actionable endotypes (hyperinflammatory C1, hypoinflammatory C2) with differential treatment responses. This network‐based understanding is catalyzing a therapeutic shift toward rationally designed poly‐pharmacology, precision immunotherapies, and advanced platforms integrating smart nanomaterials with endogenous systems. By embracing this holistic perspective, we chart a course toward mechanism‐based, personalized interventions that move beyond supportive care to genuine disease modification.

29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YWYao Wang
Yao Wang
XDXiang Dai
Xiang Dai
KLKun Liu
Kun Liu
RJRen Jing
Ren Jing
ZZZhigang Zhou
Zhigang Zhou
DWDan Wang
Dan Wang
Dysregulated metabolism in macrophages is critically involved in triggering acute lung injury (ALI) following sepsis, highlighting the importance of targeting macrophage metabolism for ALI treatment. However, the precise mechanisms dictating macrophage metabolism during ALI remains elusive. Bromodomain protein 4 (BRD4), which represents the most extensively studied member within the Bromodomain and Extraterminal (BET) protein family, has emerged as immune dictator implicating in multiple diseases. In the present study, we focused on the role of macrophage-expressed BRD4 in regulating sphingosine-1-phosphate (S1P) and glycolytic pathways during ALI, and explored its regulatory effect on PES1. Herein, we demonstrated that BRD4/PES1 axis was highly expressed in macrophages in vitro and in vivo, cascading the aberrant activation of S1P receptor 3 (S1PR3) and glycolytic determinants including hexokinase 2 (HK2), 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) and pyruvate kinase M2 (PKM2). Silencing or inhibiting BRD4 mitigated the expression levels of LPS-induced HK2, PFKFB3, PKM2, and S1PR3 by depressing PES1 in vitro. Furthermore, targeting BRD4 by JQ1 suppressed BRD4/PES1 pathway and improved ALI in septic mice by dampening glycolysis and S1PR3. Intriguingly, PES1 ablation recapitulated the effect of BRD4 inhibition on macrophages. Notably, pharmacological inhibition of S1PR3 by TY-52156 efficiently abrogated glycolysis-associated markers and alleviated lung injury. Hence, targeting the BRD4/PES1 axis emerges as a viable candidate for therapeutic intervention against sepsis-induced ALI.

29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YWYao Wang
Yao Wang
XDXiang Dai
Xiang Dai
KLKun Liu
Kun Liu
RJRen Jing
Ren Jing
ZZZhigang Zhou
Zhigang Zhou
DWDan Wang
Dan Wang
Dysregulated metabolism in macrophages is critically involved in triggering acute lung injury (ALI) following sepsis, highlighting the importance of targeting macrophage metabolism for ALI treatment. However, the precise mechanisms dictating macrophage metabolism during ALI remains elusive. Bromodomain protein 4 (BRD4), which represents the most extensively studied member within the Bromodomain and Extraterminal (BET) protein family, has emerged as immune dictator implicating in multiple diseases. In the present study, we focused on the role of macrophage-expressed BRD4 in regulating sphingosine-1-phosphate (S1P) and glycolytic pathways during ALI, and explored its regulatory effect on PES1. Herein, we demonstrated that BRD4/PES1 axis was highly expressed in macrophages in vitro and in vivo, cascading the aberrant activation of S1P receptor 3 (S1PR3) and glycolytic determinants including hexokinase 2 (HK2), 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3 (PFKFB3) and pyruvate kinase M2 (PKM2). Silencing or inhibiting BRD4 mitigated the expression levels of LPS-induced HK2, PFKFB3, PKM2, and S1PR3 by depressing PES1 in vitro. Furthermore, targeting BRD4 by JQ1 suppressed BRD4/PES1 pathway and improved ALI in septic mice by dampening glycolysis and S1PR3. Intriguingly, PES1 ablation recapitulated the effect of BRD4 inhibition on macrophages. Notably, pharmacological inhibition of S1PR3 by TY-52156 efficiently abrogated glycolysis-associated markers and alleviated lung injury. Hence, targeting the BRD4/PES1 axis emerges as a viable candidate for therapeutic intervention against sepsis-induced ALI.